AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04687696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isolytic Stretching Group
Description: Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform a contraction in the horizontal abduction direction with 20% of the maximum muscle strength. When the muscle contraction occurs, the arm will be moved quickly in 2-4 seconds towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretches. This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
Study NCT04687696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching Group Group
Description: Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier. Then, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretching exercises. This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
Study NCT05474300 — intervention group
Intervention type: OTHER
Intervention: mechanical ventilation
Description: Pressure controlled ventilation mode on mechanical ventilation
Study NCT06345677 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ViXe Xombination
Description: Combination of Xeomin and the ultrasound based delivery system (Vibe) for intravesical administration of the drug in a minimally invasive procedure
Study NCT06345677 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Sham
Description: Placebo identical in package and appearance to Xeomin together with all steps of Vibe device preparation and activation, but without the actual operation of the ultrasound energy
Study NCT04583033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Treatment components include stimulus control, sleep restriction therapy, relaxation, and cognitive therapy. Each session will last approximately one hour and will be provided on line.
Study NCT04243330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback
Description: The following components will be incorporated into the audit and feedback intervention: i) individualized facility performance data (site level), ii) frequent delivery intervals (monthly), iii) comparisons with other sites, iv) graphical and text form displays of information, v) constructive, non-punitive tone, vi) target performance or benchmark provided, and vii) specific actions or recommendations for meeting the target.
Study NCT04243330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External Facilitation
Description: Facilitation will be conducted by a team of facilitators who will employ the facilitation process to improve uptake of VA Risk ID. Trained external facilitators will flexibly deliver the facilitation process utilizing an integrated set of implementation strategies (e.g., stakeholder engagement, identification of barriers and facilitators, education, problem solving, the use of formative data, communication, and ongoing support).
Study NCT05028400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser speckle contrast imaging (LSCI)
Description: LSCI videos will be recorded automatically intraoperatively in each patient before, during, and after ICGA and/or FA in the same surgical field of view to guarantee comparability of the methods.
Study NCT05102955 — intervention group
Intervention type: OTHER
Intervention: Observational questionnaires
Description: All one Group/ Visual Function Classification System(VFCS), Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS), Communication Function Classification System(CFCS) Questionnaires will be assessed by the different raters (physiotherapists). But Visual Function Classification System(VFCS) will be assesed also by the parents.
Study NCT04321759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy
Description: CET's group-based exercises are delivered for 1.5 hours each week in a group of 6-8 participants led by a clinician and an assistant, for one year. During each of three modules (basic concepts, social cognition, CET applications), the groups focus on acquisition of adult social milestones in perspective-taking, social context appraisal, and other aspects of social cognition, with psychoeducational lectures, homework assignments, and in-group exercises. Weekly supervision sessions for the clinician trainers will include review of how patients respond to the different demands of computer-based training and group-based exercises and guidance about improving engagement in both.
Study NCT04321759 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Skills Training
Description: The psychosocial component involves weekly skills training classes delivered over one year, with modules including Communicating Effectively, Making and Keeping Friends, Making the Most of Leisure Time, Healthy Living, Using Medications Effectively, and Making the Most of a Health Care Visit (Pratt et al., 2008). Participants attend two sessions each week (normally morning and afternoon of the same day): a 90-minute session focused on a specific skill and a 60-minute session in which the specific skill is used in role-play exercises.
Study NCT06364085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromodulation programming
Description: Participants will be brought in for their standard follow-up appointments at 4-weeks, 4-months, and 1-year post-surgery. In addition to the routine care, physiological data will be extracted from the implanted device and analyzed. The physiological data will be considered along with the standard epilepsy diary to assess epileptic burden and inform device programming.~Quality of life will be measured with a series of standard questionnaires pre-surgery and at the 1-year follow-up.
Study NCT04517188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP
Description: Single topical administration
Study NCT05726344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: 4 tablets of Bisacodyl (5 mg) + 250 mL (162.5g lactulose) of lactulose + 600 mL of water + 2 L of water
Study NCT05726344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 3350
Description: 4 tablets of Bisacodyl (5 mg) + 3 bottles Polyethylene Glycol 3350 (Polyethylene glycol 3350 60 g; sodium chloride 1.46 g; potassium chloride 745 mg; Sodium bicarbonate 1.68 g; anhydrous sodium sulfate 5.68 g; pineapple flavoring 483 mg) + 3 L of water
Study NCT06195722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation
Description: parenteral drug simulation
Study NCT06076915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergame training
Description: During the exergame intervention period, the participants in the respective group will be asked to train at least two times per week for 10 minutes per session. The proposed 10 to 15 min-sessions can also be split up into multiple short training slots during the day, to thus reach the targeted 10 minutes. Moreover, the participants are allowed to train even more during their exergame-intervention period of six weeks. However, during the control period of six weeks, they are prohibited from training on the device.~The training program will start with four pre-defined programs of the Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification) program. This training program will be adapted weekly by the investigator to generate new stimuli through varying games and thereby also further support the motivation.
Study NCT05135650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05135650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotrovimab
Description: Given IV
Study NCT05135650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and nasal swab sample collection
Study NCT06029621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RATS for Thymectomy
Description: a minimally invasive surgical type for Thymoma: RATS
Study NCT06029621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS for Thymectomy
Description: a minimally invasive surgical type for Thymoma: VATS
Study NCT05121532 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-15 and Interleukin-22
Description: Serum Interleukin-15 and Interleukin-22 in non segmental vitiligo
Study NCT05385861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoliposomal irinotecan plus carboplatin
Description: Dose in phase 1 cohort:~Dose level 1= nanoliposomal irinotecan 100 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level 0= nanoliposomal irinotecan 80 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level -1= nanoliposomal irinotecan 60 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Carboplatin dose (mg) is calculated by the Calvert formula: AUC x (eGFR + 25). Cockcroft-Gault equation: eGFR (calculated Ccr)= \[(140-age) x weight x 0.85 (if female)\] / (72 x serum Cr). The maximum eGFR for dose calculation is 125 ml/min.~In Phase 2 Cohort Patients will be treated until disease progression, unacceptable toxicity or other condition meeting the treatment discontinuation criteria.
Study NCT06233071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone+ Ethinyl Estradiol Tablets-Test product
Description: Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: POND'S CHEMICAL THAILAND R.O.P
Study NCT06233071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone+ Ethinyl Estradiol Tablets-Reference product
Description: Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: Bayer Weimar GmbH und Co. KG, Germany
Study NCT03804619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated intermittent theta-burst stimulation (aiTBS)
Description: aiTBS is an effective form of non-invasive brain stimulation which has been FDA-approved for the treatment of Major Depressive Disorder (MDD)
Study NCT04700176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: During 28-day treatment cycles, patients will receive Dara 16 mg/kg intravenously (IV) at their current dose upon enrollment onto the study depending on their cycle. They will receive Dara depending on the cycle they are in. If they are on cycles 1-2 then they will receive Dara 16 mg/kg IV on days 1,8,15,22; if they are on cycles 3-6 they will receive Dara 16 mg/kg on days 1 and 15; and if they are on cycle 7 or beyond they will receive Dara 16 mg/kg on day 1.
Study NCT04700176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered at the patient's currently tolerated dose (4,3, or 2 mg po daily) on days 1-21
Study NCT04700176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Description: ATRA will be administered in a divided dose of twice daily as an oral formulation at 45mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled Dara infusion. The last administration of ATRA will be given in the evening of the day that Dara was administered
Study NCT04700176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered at 40 mg once weekly on days 1,8,15 for patients 75 years old and younger and at 20 mg once weekly on days 1,8,15 for patients older than 75.
Study NCT04793295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: MT-7117
Study NCT06264570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B-TMG supplementation
Description: B-TMG supplement (B2 riboflavin, B6 pyroxidine, B9 methylfolate, B12 methylcobalamine, S-adenosylmethionine, Trimethylglycerol (TMG), zinc sulfate) for subjects with normal COMT gene and MTHFR gene polymorphism
Study NCT06264570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B-SAM supplementation
Description: B-SAM supplement (B2 riboflavin, B6 pyroxidine, B9 folic acid, B12 adenosylcobalamin, magnesium, S-adenosylmethionine) for Subjects with COMT gene polymorphism or normal COMT gene and normal MTHFR gene
Study NCT06264570 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: B-TMG placebo
Description: B-TMG placebo for subjects with normal COMT gene and MTHFR gene polymorphism
Study NCT06264570 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: B-SAM placebo
Description: B-SAM placebo for Subjects with COMT gene polymorphism or normal COMT gene and normal MTHFR gene
Study NCT05677490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT01868048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.~Subjects receive study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
Study NCT01868048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
Study NCT05547178 — intervention group
Intervention type: OTHER
Intervention: Qualitative interview - eurythmy group
Description: Participants will be interviewed about self-perceived changes in everyday life during participation in the eurythmy intervention of the ENTAiER study.
Study NCT05547178 — intervention group
Intervention type: OTHER
Intervention: Qualitative interview - tai chi group
Description: Participants will be interviewed about self-perceived changes in everyday life during participation in the tai chi intervention of the ENTAiER study.
Study NCT05547178 — intervention group
Intervention type: OTHER
Intervention: Qualitative interview - standard care group
Description: Participants will be interviewed about self-perceived changes in everyday life during participation in the standard care group of the ENTAiER study.
Study NCT05268926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10Mg Tab
Description: dapagliflozin 10 mg/d or matched placebo
Study NCT05268926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06428578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FBM-In person
Description: Participants will receive two home visits by a CHW. Each home visit will last about 30 minutes, during which the CHW will assist the woman with community resources and help with enrolling in any state or federal nutrition and medical programs. Furthermore, the participants will be given access to a private Facebook group for nutrition, health education, and social support. Home visits will occur during the second and fifth weeks of the study.
Study NCT06428578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FBM-Virtual
Description: Participants will receive access to a virtual platform which will have information on national, state, and local food and medical resources, as well as local community resources, and will have access to a private Facebook group for nutrition, health education, and social support.
Study NCT06428578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home delivered food boxes
Description: Participants will receive weekly deliveries of a box containing fresh produce and staple goods (approximately 5 meals a week), culturally tailored meals (6 meals a week), and prepared fruit, vegetable and grain-forward meal kits (4 units a week) plus standard nutrition education materials consisting of recipes inside of the boxes. Each participant will receive one box for eight consecutive weeks.
Study NCT06428578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home delivered food boxes
Description: Participants will receive weekly deliveries of a box containing fresh produce and staple goods (approximately 5 meals a week), culturally tailored meals (6 meals a week), and prepared fruit, vegetable and grain-forward meal kits (4 units a week) plus standard nutrition education materials consisting of recipes inside of the boxes. Each participant will receive one box for eight consecutive weeks.
Study NCT05725356 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Basic body awareness therapy
Description: Participants were instructed to focus on maintaining good posture, balance, uninterrupted breathing, increased awareness, and decreasing unnecessary muscle tension.
Study NCT05725356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic body awareness therapy
Description: Participants were instructed to focus on maintaining good posture, balance, uninterrupted breathing, increased awareness, and decreasing unnecessary muscle tension.
Study NCT05182554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doctor Videos
Description: Receive ads on Facebook or through our website with videos in which health professionals tell people to get the Covid-19 vaccine. The health professionals answer common questions about the Covid-19 vaccine, such as how mRNA vaccines work, and what types of side effects to expect.
Study NCT05677490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study NCT05182554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sharing Videos
Description: Receive ads on Facebook with videos in which health professionals tell people to encourage their unvaccinated friends to get the Covid-19 vaccine.
Study NCT05182554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sharing Videos (Influencers)
Description: Receive ads on Facebook with videos in which health professionals tell people to get their most influential friends to encourage their unvaccinated friends to get the Covid-19 vaccine.
Study NCT05182554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaccine Ambassador
Description: Adults in participating geographic areas can sign up to be a vaccine ambassador on a website that the study team has built. The study team will send updates to vaccine ambassadors when new content has been posted to the website (e.g. a new video) and/or to remind the vaccine ambassadors to encourage their friends to get vaccinated. The study team will incentivize vaccine ambassadors by entering participating ambassadors into a lottery for a prize.
Study NCT05182554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video framing
Description: The same videos will be displayed using two different frames: a myth frame and a fact frame. Visitors to the vaccine content website will randomly receive one framing of each video.
Study NCT05182554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video order
Description: The order in which videos appear on the vaccine content website will be randomized.
Study NCT05243264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empower@Home
Description: The intervention is a 10-week course of internet-based cognitive behavioral therapy. During the active intervention phase, participants will receive a weekly check-in call to see how they are doing. The weekly check-in call is intended to be brief and last no more than 10 minutes on average.
Study NCT05677490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT05677490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT06548984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diaphragmatic exercises
Description: Perform controlled and supervised diaphragmatic exercises
Study NCT06548984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training
Description: Perform respiratory muscle training with controlled and supervised devices
Study NCT05677490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT05677490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV
Study NCT05677490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study NCT05677490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT05677490 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study NCT05677490 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05522439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1703
Description: SHR-1703 will be administered by SC injection.
Study NCT05522439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-1703 Placebo
Description: Matching Placebo will be administered by the SC route.
Study NCT05522439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1703 Placebo
Description: Matching Placebo will be administered by the SC route.
Study NCT05654129 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: saliva samples
Description: saliva samples (non-invasive, in the sites evaluated during the partial survey) will be perform by one of the investigators .